PXD055561

PXD055561 is an original dataset announced via ProteomeXchange.

Title	Targeted therapies restore skin barrier function and associated proteomics in atopic dermatitis
Description	Background: Atopic dermatitis (AD) is characterized by skin barrier dysfunction. The impact of targeted therapies on skin barrier function and associated barrier protein changes remains not fully identified. Objective: To investigate the skin barrier function and proteomics in AD before and after different targeted therapies. Method: 15 healthy controls and 29 adult patients with moderate-to-severe AD were enrolled. AD patients were randomized into two groups. One group received dupilumab (N = 14) and the other received abrocitinib (N = 15). Clinical assessments and skin barrier parameters (transepidermal water loss [TEWL] and hydration) were measured at baseline, 4 weeks, and 12 weeks of treatment. Skin tape strips were collected for four-dimensional data-independent acquisition-based proteomics. Results: Both therapies improved skin barrier function, with abrocitinib showing greater effects on decreasing TEWL in the non-lesional skin. The proteomic analysis identified 1237 lesional and 785 non-lesional differentially expressed proteins (DEPs) between AD patients and healthy controls, especially in pathways related to ceramide metabolism, neurobiology, and keratinocyte biology. Treatment with abrocitinib resulted in more DEPs and significantly upregulated proteins associated with the epidermal barrier while downregulating immunological and itch-related proteins. It also increased key barrier proteins (filaggrin-2 and loricrin) in lesional skin, which was not shown in the dupilumab group. Both treatments regulated specific proteins in non-lesional skin, such as grancalcin and phospholipase D3. Conclusion: The study suggests that both targeted therapies improve the skin barrier function in AD, but they have different effects on barrier proteins, with abrocitinib having stronger effects.
HostingRepository	PRIDE
AnnounceDate	2025-04-19
AnnouncementXML	Submission_2025-04-18_20:11:59.724.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Xiaobao Huang
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	timsTOF Pro

Revision	Datetime	Status	ChangeLog Entry
0	2024-09-04 12:22:30	ID requested
⏵ 1	2025-04-18 20:12:00	announced

10.1016/J.JAAD.2025.04.027;

submitter keyword: Atopic dermatitis

Abrocitinib

Dupilumab

Skin barrier function

Barrier protein

Filaggrin-2

Loricrin

Proteomics

Fang Wang
contact affiliation	The First Affiliated Hospital, Sun Yat-sen University
contact email	wangf78@mail.sysu.edu.cn
lab head
Xiaobao Huang
contact affiliation	The First Affiliated Hospital, Sun Yat-sen University
contact email	huangxb8@mail2.sysu.edu.cn
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/04/PXD055561

PRIDE project URI

• PRIDE
  1. PXD055561
     1. Label: PRIDE project
     2. Name: Targeted therapies restore skin barrier function and associated proteomics in atopic dermatitis